ARZERRA Approved in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL1

View the PFS data: ARZERRA + FC

Reference: 1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2016.